Brown University’s Executive Masters in Healthcare Leadership: A Mission to Transform
Mid-career students at Brown University’s new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos that slow innovations in the delivery and financing of healthcare.
Mid-career students at Brown University’s new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos that slow innovations in the delivery and financing of healthcare.
As the US healthcare system stumbles toward a new consensus built around the “triple aim” of increased access, improved quality, and lower cost, the push is on for new ideas that can test the boundaries of current practice. The Affordable Care Act (ACA) creates a range of incentives to promote this goal, which has added to the momentum around novel reform approaches. Business management schools have jumped with gusto into the fray, providing much of the intellectual heft for integrative, outcomes-oriented programs that stress patient wellness and require medicines to do more than just treat disease.
One institution, Brown University, has gone a step further than many of its counterparts, with a new 16-month Executive Master of Healthcare Leadership (EMHL) program dedicated to empowering mid-career health professionals with the diverse interests, skills and capabilities to challenge that status quo and “transform” healthcare as we now know it.
For more on this article, click on this month’s issue of Pharm Exec.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
